TrialInternational journal of molecular sciences2023

A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy.

Karen Gambaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.